Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CEO Buying: Accuray CEO Purchases 100,000 Shares Of Stock (ARAY)

|Includes: Accuray Incorporated (ARAY)

Accuray (NASDAQ:ARAY) CEO Levine Joshua purchased 100,000 shares of the stock on the open market in a transaction dated November 3th. The purchase is weighted 12.3% of his whole holdings. The stock was purchased at price of $6.34 per share, with a total value of $634,000. Following the completion of the purchase, the CEO now directly owns 811,634 shares of the company's stock, valued at approximately $5,437,947.

Shares of Accuray (NASDAQ:ARAY) traded up 5.02% on Thursday, hitting $6.7. 1,077,489 shares of the company's stock traded hands. Accuray has a 52 week low of $5.99 and a 52 week high of $10.85. The stock has a 50-day moving average of $7.25 and a 200-day moving average of $8.11. The company's market cap is $517.84 million.

Accuray (NASDAQ:ARAY) last announced its earnings results on October 29rd. The company reported ($0.28) earnings per share (NYSEARCA:EPS) for the quarter, lower than the consensus estimate of ($0.13) by $0.15. The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $88.90 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company's revenue for the quarter was up .75% on a year-over-year basis.

ARAY has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Accuray from a "neutral" rating to an "underperform" rating in a research note. They now have a $6.75 price target on the stock. The company has an average rating of "Hold" and an average target price of $10.95.

Accuray is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient.

In the past 5 years, Accuray is increasing its revenue consistently.

Accuray has negative Free Cash flow.